Drug intelligence / Profile preview

Clarix Flo

Development stage
Unknown
Lead developer
BioTissue
Administration
Intravesical, Intraarticular, Intralesional
01

Overview

Clarix Flo (CLARIX® FLO) is a sterile, acellular, particulate human amniotic membrane and umbilical cord tissue allograft developed by BioTissue. It is processed from donated human placental tissue obtained via voluntary Cesarean section donations and does not contain living cells. Clarix Flo is rich in extracellular matrix proteins, growth factors (such as TGF-β, EGF, and PDGF), cytokines, and hyaluronic acid, which collectively promote tissue repair, reduce inflammation, and minimize scarring. It is administered via localized injections (such as intradetrusor injections for bladder conditions or intra-articular/intralesional injections for musculoskeletal injuries) to act as a biological scaffold that restarts the body's natural healing process. Clarix Flo is primarily investigated for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) and is also used for chronic soft tissue and musculoskeletal conditions, including plantar fasciitis, Achilles tendonitis, and osteoarthritis.

Brand names
CLARIX FLO
Other names
micronized amniotic membranemicronized amniotic membrane and umbilical cord tissueprocessed amniotic fluidprocessed amniotic membrane
02

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on Clarix Flo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clarix Flo.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call